Experts Perspectives: Navigating Newly Diagnosed MM to Early Relapse - Episode 3
Transplant-ineligible Patients with Newly Diagnosed Multiple Myeloma: CEPHEUS, IMROZ, and BENEFIT Studies
Panelists discuss the CEPHEUS trial results for newly diagnosed patients who are not transplant eligible, highlighting key takeaways. They also compare the CEPHEUS data with other quadruplet regimens in the non–transplant-eligible space, such as Isa-VRd.
Dr Ajai Chari to Dr Callander: Switching to those newly diagnosed patients who are not transplant eligible or for whom transplant is not planned as initial therapy, Dr Callander, can you summarize the CEPHEUS data results presented at IMS and your key takeaways from this trial?
Resource Links
- OA-63 IMS 2024 CEPHEUS or (see page 11)
Dr Ajai Chari to Dr Martin: How do CEPHEUS data compare to other quadruplet regimens in the non–transplant-eligible space, like Isa-VRd?
Resource Link
Resource Link:
Related Content:
